Azacitidine and nivolumab therapy results in complete remission for 22 percent of patients with relapsed/refractory acute myeloid leukemia; biomarkers found for patients likely to respond HOUSTON ― A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center. Results from the […]
